Read More

Vycellix and Moffitt Cancer Center Announce a Collaborative Research Study to Evaluate Novel Product Candidates for Improving Adoptive Cell Immunotherapies for Cancer

Studies designed to enhance T cell and NK cell potencies through improved genetic modification and increased cytolytic granules SARASOTA and TAMPA, Fla. – Feb. 27, 2017 – Vycellix, Inc., a biopharmaceutical company advancing innovative small molecules to enhance cellular therapies, facilitate manufacturing processes and optimize human immune response against disease, today announced that it has […]

Read More

Vycellix’s CEO to Present Novel Approaches to Adoptive Cancer Immunotherapy at Innate Killer Summit

New Products Enhance Genetic Modification of Lymphocytes  and Significantly Amplify Cancer Killing Capacity Sarasota, Fla. – May 2, 2016 – Vycellix, Inc., a privately-held biotechnology company advancing novel products capable of optimizing human immune response against disease with a focus on cancers, today announced that its CEO, Evren Alici, M.D., Ph.D., will present at the […]